Quick Answer
LENZ Therapeutics, Inc. reported Total Assets of $305.88 million for the year ending 2025.
- LENZ Therapeutics, Inc. showed an increase of +42.1% in Total Assets from 2024 to 2025.
- This data is from LENZ Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $387.11 million | Q3 2021: $416.15 million | Q1 2022: $378.61 million | Q2 2022: $353.79 million | Q3 2022: $334.85 million | Q1 2023: $310.00 million | Q2 2023: $287.04 million | Q3 2023: $266.23 million | Q1 2024: $217.32 million | Q2 2024: $202.64 million | Q3 2024: $224.01 million | Q1 2025: $201.25 million | Q2 2025: $217.33 million | Q3 2025: $210.70 million.
- Over the full 6 years of available data (2020 to 2025), LENZ Therapeutics, Inc.'s Total Assets has grown by 1,255.6%.
- Historical annual values: Fiscal year 2025: $305.88 million | Fiscal year 2024: $215.30 million | Fiscal year 2023: $70.38 million | Fiscal year 2022: $321.90 million | Fiscal year 2021: $401.99 million | Fiscal year 2020: $22.56 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: